IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v11y2020i1d10.1038_s41467-020-15030-4.html
   My bibliography  Save this article

Escherichia coli adhesion portion FimH functions as an adjuvant for cancer immunotherapy

Author

Listed:
  • Wei Zhang

    (Fudan University)

  • Li Xu

    (Fudan University)

  • Hae-Bin Park

    (Fudan University
    Yeungnam University)

  • Juyoung Hwang

    (Fudan University
    Yeungnam University)

  • Minseok Kwak

    (Pukyong National University)

  • Peter C. W. Lee

    (University of Ulsan College of Medicine, ASAN Medical Center)

  • Guang Liang

    (Wenzhou Medical University, Wenzhou)

  • Xiaoyan Zhang

    (Fudan University)

  • Jianqing Xu

    (Fudan University)

  • Jun-O Jin

    (Fudan University
    Yeungnam University)

Abstract

Induction of antigen-specific immune activation by the maturation of dendritic cells (DCs) is a strategy used for cancer immunotherapy. In this study, we find that FimH, which is an Escherichia coli adhesion portion, induces toll-like receptor 4-dependent and myeloid differentiation protein 2-independent DC maturation in mice in vivo. A combined treatment regimen with FimH and antigen promotes antigen-specific immune activation, including proliferation of T cells, production of IFN-γ and TNF-α, and infiltration of effector T cells into tumors, which consequently inhibits tumor growth in mice in vivo against melanoma and carcinoma. In addition, combined therapeutic treatment of anti-PD-L1 antibodies and FimH treatment efficiently inhibits CT26 tumor growth in BALB/c mice. Finally, FimH promotes human peripheral blood DC activation and syngeneic T-cell proliferation and activation. Taken together, these findings demonstrate that FimH can be a useful adjuvant for cancer immunotherapy.

Suggested Citation

  • Wei Zhang & Li Xu & Hae-Bin Park & Juyoung Hwang & Minseok Kwak & Peter C. W. Lee & Guang Liang & Xiaoyan Zhang & Jianqing Xu & Jun-O Jin, 2020. "Escherichia coli adhesion portion FimH functions as an adjuvant for cancer immunotherapy," Nature Communications, Nature, vol. 11(1), pages 1-14, December.
    • Handle: RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-15030-4
    DOI: 10.1038/s41467-020-15030-4
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-020-15030-4
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-020-15030-4?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-15030-4. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.